YMAB — Y-mAbs Therapeutics Share News
0.000.00%
Last trade - 00:00- $390.32m
- $328.02m
- $87.69m
Y-mAbs Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Y-mAbs Therapeutics Q2 Net Income USD -6.3 Million
Y-mAbs Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Y-mAbs Therapeutics rises on approval of cancer drug in Brazil
Brief: Y-mAbs’ Danyelza (naxitamab-gqgk) For Treatment Of High-Risk Neuroblastoma Approved In Brazil
U.S. STOCKS ON THE MOVE-First Citizens BancShares, Sarepta, Celsius Holdings
U.S. STOCKS ON THE MOVE-Taboola, US banks, Copper miners
Y-mAbs Therapeutics rises after Wedbush upgrades to 'outperform'
Y-mAbs Therapeutics gains on raising forecast for 2023 product revenue
Brief: Y-Mabs Reports First Quarter 2023 Financial Results
Brief: Y-mAbs Therapeutics posts Q1 product revenue USD 20.3 million
Y-mAbs Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Y-mAbs Announces First Patient Dosed In Phase 1 Clinical Trial Of GD2-SADA
U.S. STOCKS ON THE MOVE-Icosavax, U.S. solar companies, Nikola, energy firms
Y-mAbs Therapeutics rises on Q4 profit beat, strong revenue growth
Y-mAbs Therapeutics jumps on upbeat Q4 profit, strong revenue growth
U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings
Brief: Y-Mabs Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Y-mAbs Therapeutics Inc reports results for the quarter ended in December - Earnings Summary